Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus

Study Overview

The purpose of this research study is to measure how much of the study drug (Afrezza) gets into your blood
after a single dose and measure how well it works to control your blood sugar level. We also want to make sure
this study drug is safe for children and adolescents between 4 and 17 years old.

IRB Number: 1810897000
Research Study Identifier: TX10301
Principal Investigator: Linda DiMeglio, MD

Recruitment Status

Open

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

* Your Email

* First Name

Last Name

* Your Phone

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Recruitment Status

Open

Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus

Study Overview

Recruitment Status

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact Us

Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus

Study Overview

Recruitment Status

Contact the research team to learn more about this study. Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact Us

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required